{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:54:10Z","timestamp":1745470450834,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"Suppl. 1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:p>&lt;i&gt;Objective:&lt;\/i&gt; To evaluatethe efficacy and safety of OxyContin\u00ae tablets (controlled-release oxycodone hydrochloride: 5, 10, 20, and 40 mg) in relieving moderate to severe cancer pain. &lt;i&gt;Method:&lt;\/i&gt; A multicenter, open-label, prospective, self-controlled clinical trial was used.&lt;i&gt; Results:&lt;\/i&gt; Pain was relieved in 89.1% of patients within 1 h after drug administration. OxyContin\u00ae tablets showed good clinical efficacy in relieving both moderate and severe cancer pain. Compared with baseline average pain scores of 6.9 \u00b1 1.4, subjects had lower average pain scores after administration of OxyContin\u00ae tablets: 2.7 \u00b1 1.8 after 1 week and 2.1 \u00b1 1.5 after 2 weeks. Response rate reached 75.0% at the end of the 1st week and was maintained at approximately 90% from the 3rd to the 8th week. The most common adverse drug reactions (ADRs) caused by OxyContin\u00aetablets were, in descending order of incidence rate: constipation (25.5%), nausea (13.3%), vomiting (6.2%), lethargy (3.7%), and dysuria (2.1%). All these ADRs could be decreased by preventive medications. &lt;i&gt;Conclusion:&lt;\/i&gt; OxyContin\u00ae tablets demonstrated fast onset of cancer pain control, superior efficacy in relieving both moderate and severe cancer pain and a good safety profile.<\/jats:p>","DOI":"10.1159\/000143218","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T12:12:12Z","timestamp":1220271132000},"page":"46-51","source":"Crossref","is-referenced-by-count":7,"title":["Postmarketing Surveillance Study of OxyContin\u00ae Tablets for Relieving Moderate to Severe Cancer Pain"],"prefix":"10.1159","volume":"74","author":[{"given":"Shi Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2125.1996.00481.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS1090-3801%2898%2990020-9"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0304-3959%2897%2900072-9"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.pain.2006.02.006"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/143218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/143218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:19:22Z","timestamp":1745457562000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000143218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":4,"journal-issue":{"issue":"Suppl. 1","published-online":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000143218","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2008]]}}}